0001209191-18-053540.txt : 20181002 0001209191-18-053540.hdr.sgml : 20181002 20181002214201 ACCESSION NUMBER: 0001209191-18-053540 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180928 FILED AS OF DATE: 20181002 DATE AS OF CHANGE: 20181002 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Topper James N CENTRAL INDEX KEY: 0001341382 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38670 FILM NUMBER: 181103630 MAIL ADDRESS: STREET 1: 550 HAMILTON AVENUE, SUITE 100 CITY: PALO ALTO STATE: CA ZIP: 94301 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Entasis Therapeutics Holdings Inc. CENTRAL INDEX KEY: 0001724344 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 824592913 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 GATEHOUSE DRIVE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 810-0120 MAIL ADDRESS: STREET 1: 35 GATEHOUSE DRIVE CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Entasis Therapeutics Ltd DATE OF NAME CHANGE: 20171204 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-09-28 0 0001724344 Entasis Therapeutics Holdings Inc. ETTX 0001341382 Topper James N C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451 1 0 1 0 Common Stock 2018-09-28 4 C 0 337707 A 337707 I See Footnote Common Stock 2018-09-28 4 C 0 251487 A 589194 I See Footnote Common Stock 2018-09-28 4 C 0 320898 A 974066 I See Footnote Common Stock 2018-09-28 4 P 0 375887 15.00 A 1349953 I See Footnote Series B Convertible Preferred Stock 2018-09-28 4 C 0 7000000 0.00 D Common Stock 337707 0 I See Footnote Series B-1 Tranche A Convertible Preferred Stock 2018-09-28 4 C 0 5212833 0.00 D Common Stock 251487 0 I See Footnote Series B-1 Tranche B Convertible Preferred Stock 2018-09-28 4 C 0 6651574 0.00 D Common Stock 320898 0 I See Footnote Each share of Series B Preferred Stock, Series B-1 Tranche A Convertible Preferred Stock and Series B-1 Tranche B Convertible Preferred Stock (collectively, the "Preferred Stock") automatically converted into Common Stock on a 20.728-for-one basis upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. The reportable securities are held directly by Frazier Life Sciences VIII, L.P. ("FLS LP"). FHM Life Sciences VIII, L.P. ("FHM LP") is the general partner of FLS LP. FHM Life Sciences VIII, L.L.C. ("FHM LLC") is the general partner of FHM LP. The Reporting Person, a director of the Issuer, is a managing member of FHM LLC. The Reporting Person disclaims beneficial ownership of the securities held by FLS LP except, to the extent of his pecuniary interest in such shares. This number includes an aggregate of 63,974 shares of Common Stock received upon the conversion of the Issuer's Preferred Stock as payment of the accrued dividends through September 27, 2018. No dividends will accrue after September 27, 2018. /s/ Jason Minio, Attorney-in-Fact 2018-10-02